Subscribe
shutterstock_1876891582_seda_yalova
21 December 2023Big PharmaMarisa Woutersen

BioNTech wins latest round in Covid-19 patent clash

CureVac suffers a blow following a favourable earlier opinion delivered by the German Federal Patent Court | Decision invalidates a patent related to mRNA tech.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
BioNTech and Pfizer challenge Moderna’s COVID-19 vaccine patent
29 August 2023   Inter partes review challenges broad claims and monopolisation over mRNA tech amidst existing legal dispute | Alnylam set to appeal separate court ruling against Moderna.
Big Pharma
Moderna, Pfizer and BioNTech hit with COVID-19 vaccine lawsuits over mRNA tech
8 June 2023   Promosome claimed it shared mRNA tech with the trio, who went on to make hugely successful vaccines | The small biotech wants a cut of more than $100 billion allegedly made by the big pharma companies.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Big Pharma
Moderna, Pfizer and BioNTech hit with COVID-19 vaccine lawsuits over mRNA tech
8 June 2023   Promosome claimed it shared mRNA tech with the trio, who went on to make hugely successful vaccines | The small biotech wants a cut of more than $100 billion allegedly made by the big pharma companies.
Big Pharma
BioNTech and Pfizer challenge Moderna’s COVID-19 vaccine patent
29 August 2023   Inter partes review challenges broad claims and monopolisation over mRNA tech amidst existing legal dispute | Alnylam set to appeal separate court ruling against Moderna.

More on this story

Big Pharma
Moderna, Pfizer and BioNTech hit with COVID-19 vaccine lawsuits over mRNA tech
8 June 2023   Promosome claimed it shared mRNA tech with the trio, who went on to make hugely successful vaccines | The small biotech wants a cut of more than $100 billion allegedly made by the big pharma companies.
Big Pharma
BioNTech and Pfizer challenge Moderna’s COVID-19 vaccine patent
29 August 2023   Inter partes review challenges broad claims and monopolisation over mRNA tech amidst existing legal dispute | Alnylam set to appeal separate court ruling against Moderna.

More features

Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York
UPC deals further blow to Dexcom in glucose monitor dispute with Abbott
‘A marathon and a sprint at the same time’: How we won $452m damages